DYAI Dyadic International, Inc.
Dyadic International, Inc. (DYAI) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.7% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.